BRIEF-FDA accepts Bristol-Myers Squibb’s application for Opdivo

* U.S. Food and Drug Administration (fda) accepts Bristol-Myers Squibb’s application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review Source text for Eikon: Further company coverage: